PF 4447943
Alternative Names: PDE9i; PF-04447943; PF-4447943Latest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Class Antianaemics; Neuropsychotherapeutics
- Mechanism of Action Phosphodiesterase 9A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sickle cell anaemia
- Discontinued Alzheimer's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in Belgium (PO)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in Italy (PO)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in Netherlands (PO)